RIBOMIC Inc. (4591.T) — English Disclosures

RIBOMIC Inc. (4591.T) Growth Market

All TDNet disclosures translated to English by Pulse News Wire.

Disclosures

Jan 14, 2026 — Mar 18, 2026

Date Range

GROWTH

Market Segment

Disclosures

Date	Type	Headline	PDF
Mar 18	Other	RIBOMIC: Submits Phase III Clinical Trial Application for Achondroplasia Treatment	PDF
Mar 17	Equity Issuance	RIBOMIC: Adjusts Funding Purposes for Rights Issues	PDF
Mar 17	Equity Issuance	RIBOMIC: Adjusts Funding Allocation Dates for Equity Warrants	PDF
Mar 10	Other	RIBOMIC Announces Positive Phase II Clinical Trial Results for Achondroplasia Treatment	PDF

Disclosure Types

Other: 2 Equity Issuance: 2

Frequently Asked Questions

Where can I read RIBOMIC Inc.'s disclosures in English?

Pulse News Wire translates all TDNet filings for RIBOMIC Inc. (4591.T) to English. 4 disclosures have been translated since Jan 14, 2026.

How many disclosures has RIBOMIC Inc. filed on TDNet?

Pulse News Wire has translated 4 disclosures for RIBOMIC Inc. since Jan 14, 2026.

Does RIBOMIC Inc. publish English IR materials?

No. RIBOMIC Inc. is listed on the GROWTH Market and has no English disclosure requirement. Pulse News Wire is the only English-language source for these filings.

What types of disclosures has RIBOMIC Inc. filed?

RIBOMIC Inc. has filed the following types of disclosures on TDNet: Other (2), Equity Issuance (2).

English translations for all 4,436 JPX-listed companies.

Including the 2,300 Standard and Growth Market companies with no other English source.

See Pricing Browse Articles